论文部分内容阅读
目的观察雷贝拉唑新三联疗法治疗幽门螺杆菌(Helicobacter pylori,简称Hp)十二指肠溃疡(Du-odenal Ulcer,简称DU)的疗效及安全性。方法按随机化原则分为A组(n=46,雷贝拉唑20 mg+阿莫西林1.0+左氧氟沙星0.2,2次/d,口服)和B组(n=46,奥美拉唑20 mg+阿莫西林1.0+克拉霉素0.5,2次/d,口服),疗程1周。疗程结束4周后复查胃镜并检测Hp。结果两组Hp根除率为93.48%~73.91%,溃疡愈合率为95.7%~91.3%。结论雷贝拉唑新三联疗法治疗HP阳性DU,疗效高,安全可靠。
Objective To observe the efficacy and safety of rabeprazole triple therapy in the treatment of Helicobacter pylori (DU) patients with duodenal ulcer (DU). Methods According to the principle of randomization, the patients were divided into group A (n = 46, rabeprazole 20 mg + amoxicillin 1.0 + levofloxacin 0.2, twice daily / d) and group B (n = 46, omeprazole 20 mg + Moxillin 1.0 + Clarithromycin 0.5,2 times / d, orally) for 1 week. Gastroscope was examined 4 weeks after the end of treatment and Hp was detected. Results The eradication rate of Hp between the two groups was 93.48% ~ 73.91%, and the healing rate of ulcer was 95.7% ~ 91.3%. Conclusion Rabeprazole new triple therapy for HP-positive DU, high efficacy, safe and reliable.